NCT06543550View on ClinicalTrials.gov

Comparison Between the Effects of Implantable Gestrinone and Oral Dienogest in the Treatment of Endometriosis

PHASE4RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

October 31, 2025

Conditions
Endometriosis
Interventions
DRUG

Implantable gestrinone

1.6mg/kg of weight of gestrinone in pellets (bio meds Brasil, Florianópolis, Brazil) subcutaneously, in the gluteal region.

DRUG

Oral Dienogest

Administered orally at 2 mg daily

Trial Locations (4)

70.390-150

RECRUITING

Gm Ignacio Atividade Medica LTDA, Brasília

58.400-506

RECRUITING

Instituto Longevite Servicos Medicos LTDA, Campina Grande

12.246-876

RECRUITING

Jpml Clinica Medica LTDA, São José dos Campos

05.688-021

RECRUITING

Dra Juliana Bicca Endocrinologia e Medicina Funcional LTDA, São Paulo

Sponsors
All Listed Sponsors
lead

Bio Meds Pharmaceutica Ltda

INDUSTRY